An observational study in Neoplasms and Venous Thromboembolism, sponsored by Floralis. Completed at 49 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-06.
Sponsored by Floralis · Observational
Treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of LMWH (Low Molecular Weight Heparin) instead of VKA (Vitamin K Antagonist) treatment during 6 months. International recommendations have diffused this option.It is necessary to evaluate the compliance of physicians to this treatment by measuring the number of patients with cancer treated with long term use of LMWH.
9,610 studies on the registry are indexed under Neoplasms; 2,508 are open to participants now.
This study's enrollment of 502 is above the median of 202 across 1,742 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Floralis is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients with cancer present in the clinic, hospital, out patients diagnosed with a VTE during the 6 previous months
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All patients with cancer present in the clinic, hospital, out patients diagnosed with a VTE during the 6 previous months. VTE can be symptomatic or asymptomatic, can be located close to a central line, and of any type (DVT, PE, SVT)
Exclusion Criteria:
All patients with cancer present in the clinic, hospital, out patient diagnosed with a VTE during the 6 previous months.
Procedure: VTE treatment in cancer patient description
proportion of patients treated for evolutive VTE according to international recommendations
Evaluation of the adherence to recommendations of VTE treatment in cancer patients
Proportion of patients treated for evolutive VTE according to international recommandations Patients could be hospitalised or could be out patient
Time frame: At baseline (J0)
Evaluation of VTE disease according to cancer diagnosis (proportion of SVT (Superficial Venous Thrombosis), DVT (Deep Venous Thrombosis), PE (Pulmonary Embolism)
Percentage of VTE (PE,DVT,SVT)and cancer type
Time frame: At baseline (J0)
Proportion of asymptomatic VTE disease for this population
percentage of VTE and cancer status (local, metastatic)
Time frame: At baseline (J0)
Feasibility of self injections for VTE treatment in cancer patients.
percentage of patients practising self injections
Time frame: At baseline (J0)
Proportion of patients with catheter thrombosis
Percentage of patients receiving novel cancer therapies
Time frame: At baseline (J0)
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.